NCT01592500View on ClinicalTrials.gov

Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Pediatric Growth Hormone Deficiency
Interventions
DRUG

MOD-4023

Once weekly subcutaneous injection

DRUG

Somatropin

Once daily subcutaneous injection of Genotropin

Trial Locations (4)

Unknown

"Children's Hospital P. A. Kyriakou", Athens

Buda Children's Hospital, Budapest

Heim Pal Children's Hospital, Budapest

Children's University Hospital, Košice

All Listed Sponsors
lead

OPKO Health, Inc.

INDUSTRY

NCT01592500 - Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children | Biotech Hunter | Biotech Hunter